Action ARDS ARIDIS PHARMACEUTICALS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Aridis Pharmaceuticals, Inc.

Actions

ARDS

US0403341045

Marché Fermé - OTC Markets
Autres places de cotation
 19:08:39 14/05/2024 		Varia. 5j. Varia. 1 janv.
0,06 USD -4,00 % Graphique intraday de Aridis Pharmaceuticals, Inc. -9,09 % -14,41 %
2023 Aridis Pharmaceuticals, Inc. publie ses résultats pour le troisième trimestre et les neuf mois clos le 30 septembre 2023 CI
2023 Aridis Pharmaceuticals, Inc. publie ses résultats pour le deuxième trimestre et le semestre clos le 30 juin 2023 CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Aridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until January 12, 2024
Aridis Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Aridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business Update
Certain Options of Aridis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-SEP-2023.
Certain Warrants of Aridis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-SEP-2023.
Certain Pre-Funded Warrant of Aridis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-SEP-2023.
Certain Common Stock of Aridis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-SEP-2023.
Aridis Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Aridis Pharmaceuticals : Termination of Material Agreement - Form 8-K
Aridis Pharmaceuticals, Inc. Announces Resignation as Chief Financial Officer
Aridis Pharmaceuticals Announces $2 Million Offering
CapitalGainsReport Penny Stock Bounce List: EPAZ, ARDS, FRTX, GNPX
Aridis Pharmaceuticals, Inc.(OTCPK:ARDS) dropped from S&P TMI Index
Aridis Pharmaceuticals : Accelaration/Increase of Financial Obligation - Form 8-K
Sector Update: Health Care Stocks Steady Premarket Tuesday
Aridis Pharmaceuticals, European Regulator Agree on Pneumonia Phase 3 Study Parameters; Shares Jump Premarket
Aridis Pharmaceuticals, Inc.(OTCPK:ARDS) dropped from NASDAQ Composite Index
Aridis Pharmaceuticals Reaches Agreement for Phase 3 Study of Pneumonia Treatment in Europe; Shares Jump After Hours
Aridis Receives Agreement from the European Medicines Agency (EMA) on the Clinical Study Design and a Single Confirmatory Phase 3 Study of AR-301
Aridis Receives Agreement from the European Medicines Agency on the Clinical Study Design and A Single Confirmatory Phase 3 Study of AR-301
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action ARDS
  4. Actualités Aridis Pharmaceuticals, Inc.
  5. Autres langues